Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting
about
Routine viral load monitoring versus standard care for reducing morbidity and mortality in adolescent and adult patients living with HIV on antiretroviral therapy (ART)Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South AfricaKericho CLinic-based ART Diagnostic Evaluation (CLADE): design, accrual, and baseline characteristics of a randomized controlled trial conducted in predominately rural, district-level, HIV clinics of KenyaA cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics.Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic AnalysisEarly clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.Comparative effectiveness of HIV testing and treatment in highly endemic regions.Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.A clinical prediction score in addition to WHO criteria for anti-retroviral treatment failure in resource-limited settings--experience from Lesotho.Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in NigeriaHealthcare infrastructure and emotional support are predictors of CD4 cell counts and quality of life indices of patients on antiretroviral treatment in Free State Province, South Africa.Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.Pooling strategies to reduce the cost of HIV-1 RNA load monitoring in a resource-limited setting.Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, TanzaniaCost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapyVirological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trialHIV treatment and care in resource-constrained environments: challenges for the next decade.Statistical Analysis and Evaluation of CD4 Count after 6 Months on ART.Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Treatment switching in South Indian patients on HAART: what are the predictors and consequences?Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapyAccuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy - the IeDEA Southern Africa CollaborationCD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic.Adult combination antiretroviral therapy in sub-Saharan Africa: lessons from Botswana and future challenges.HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional studyChallenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.Early initiation of antiretroviral therapy and universal HIV testing in sub-Saharan Africa: has WHO offered a milestone for HIV prevention?HIV drug resistance mutations following poor adherence in HIV-infected patient: a case report.A Portable, Pressure Driven, Room Temperature Nucleic Acid Extraction and Storage System for Point of Care Molecular Diagnostics.On-chip sample preparation by controlled release of antibodies for simple CD4 counting.HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.Dried Blood Spots for Use in HIV-Related Epidemiological Studies in Resource-Limited Settings
P2860
Q24203980-35D853D4-FAB6-41F7-BF85-FAC28CDEFA25Q28477379-9F78924A-1532-49BC-98AD-D2E1F556370CQ28649524-E2302015-6C7D-46B9-BA9B-8F40BCA83683Q33543151-F3875228-6EC3-469F-AA3C-8FB1BF1C8CDFQ33737122-F544AC31-50AB-4813-8C91-E5BE68792A00Q33820144-92FC2962-1E63-4B25-B00C-984E183BFB40Q34064269-E9DCFCE2-8199-47E6-9740-A038DA78142AQ34065414-DF786994-6F38-4C72-B813-E2F80A3811DFQ34243531-476E08EF-D82C-4AB2-ACBB-83A72CA70DD6Q34353431-A7FB8E8E-FD20-4DA2-90CF-774D810DAD39Q34464667-8082ACC4-6F1A-48B7-8D27-61126AD6288DQ34604679-EC1299FE-14A6-4EC4-B137-FDDB79C36B64Q34618712-C2210A62-F9DB-42A2-9983-BEA7F192C139Q34803017-F14778C7-83FB-493F-8771-90E56B182969Q35019884-01ECA9CC-7D15-4705-9F2E-485B37CBD546Q35357751-2093A972-B08C-4A54-9966-31F3137D7FFAQ35504333-85CD977F-1DA7-42FB-8601-898349C689C7Q36090721-09B5C6F6-4919-40AE-AB00-864F0A9F5EF5Q36177549-2AA23241-C250-44ED-A9FA-307F03BDE1D6Q36179320-73359BF7-8B28-4275-94F3-BFF716A66598Q36386806-745F160D-B5DA-404F-8107-BAF63CB5E433Q36491048-32CBD4EB-BC25-4FB3-92A5-E29665EE2157Q36669337-852C78CF-2BDC-4C92-AE02-88444C3877A7Q36787819-5DB03166-D2E8-4100-A58C-F7697D3DC227Q37043399-17694885-6266-4CD9-A4A1-8A0AB0A11449Q37199247-02AD7B99-5249-42F6-9BE2-CEA964636E70Q37325907-2C1E912D-CD50-4B8E-BF4D-930B339CBDDEQ37375398-114F2FB7-A318-4C36-8976-F93204FF6CCFQ37403995-DC822FF2-7317-44A6-A1E0-C2BC90F33CC5Q37415603-0879B595-2644-4793-B299-C2C0121BC22EQ37580882-DF2490DB-A037-49BA-AAF2-075A1718C4EEQ37955946-134EC0D0-F30A-4BF3-BE90-060D7619FC56Q38426164-6C16EF7F-8E32-4124-9296-7468883882F9Q41103180-1B1F54B3-F057-4A08-918A-39145B30BEFEQ42279117-C7C6410A-C742-40C4-862E-F32C636E0DD3Q51544856-8192ED16-CD0D-4F14-80C4-4FBFC1828897Q53165838-80A80613-7299-4C1B-8E5F-06C74D76B79EQ58488463-8CEF253B-0F8F-48E8-8056-AE65296FF7D6
P2860
Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Utility of CD4 cell counts for ...... in a resource-limited setting
@ast
Utility of CD4 cell counts for ...... in a resource-limited setting
@en
type
label
Utility of CD4 cell counts for ...... in a resource-limited setting
@ast
Utility of CD4 cell counts for ...... in a resource-limited setting
@en
prefLabel
Utility of CD4 cell counts for ...... in a resource-limited setting
@ast
Utility of CD4 cell counts for ...... in a resource-limited setting
@en
P2860
P50
P356
P1476
Utility of CD4 cell counts for ...... in a resource-limited setting
@en
P2860
P2888
P356
10.1186/1471-2334-8-89
P577
2008-07-04T00:00:00Z